natgillin/translations-raw huggingface dataset:
Deltagerne ved dag 1.765 i periode C omfattede 33 af de 58 abatacept-modtagere fra periode B, 30 af de 59 placebo-modtagere fra periode B og 13 af de 36 patienter fra periode A, der ikke responderede på behandlingen.
Participants in Period C at day 1765 included 33 of the 58 Period B abatacept recipients, 30 of the 59 Period B placebo recipients, and 13 of the 36 Period A non-responders.
Deltoidmusklen
Deltoid
Deltoidmusklen er det anbefalede injektionssted hos børn og unge.
The deltoid muscle is the preferred site for injection in children and adolescents.
Deltoidmusklen er det anbefalede injektionssted hos unge og voksne.
The deltoid muscle is the preferred site for injection in adults.
Deltoidmusklen er det anbefalede injektionssted hos voksne og unge.
The deltoid muscle is the preferred site for injection in adults and adolescents.
Deltyba anvendes hos voksne med lungetuberkulose, der er multiresistent (resistent i det mindste over for isoniazid og rifampicin, som er to almindeligt anvendte lægemidler mod tuberkulose).
Deltyba is used in adults with tuberculosis that is affecting the lung and that is multi-drug resistant (resistant to at least isoniazid and rifampicin, two standard anti-tuberculosis medicines).
Deltyba er et lægemiddel mod tuberkulose og indeholder det aktive stof delamanid.
Deltyba is a tuberculosis medicine that contains the active substance delamanid.
Deltyba fås kun på recept, og behandlingen bør iværksættes og overvåges af en læge med erfaring i behandling af multiresistent tuberkulose.
Deltyba can only be obtained with a prescription and treatment should be started and monitored by a doctor who is experienced in the treatment of multi-drug resistant tuberculosis.
Deltyba gives i seks måneder sammen med andre standardlægemidler.
Deltyba is given for 6 months together with other standard medicines.
Deltyba leveres i pakninger med 40 eller 48 filmovertrukne tabletter i aluminium/aluminium blisterpakninger eller i gule glas med 50 eller 300 tabletter.
Deltyba is supplied in packs of 40 or 48 film-coated tablets in aluminium/aluminium blisters, or in amber glass bottles of 50 or 300 tablets.
Deltyba må heller ikke anvendes hos patienter, der får visse andre lægemidler, som påvirker nedbrydningen af Deltyba i kroppen.
It must also not be used in patients who are taking certain other medicines that affect the way Deltyba is broken down in the body.
Deltyba må ikke anvendes hos patienter med lavt indhold i blodet af proteinet albumin.
Deltyba must not be used in patients who have low levels of albumin (a blood protein).
Delvis brugte hætteglas skal bortkastes.
Partially used vials must be discarded.
Delvis brugte hætteglas skal kasseres.
Discard partially-used vials.
Delvis CyR n (%)
Partial CyR n (%)
Delvis heling ( ≥ 75%)
Partial clearance ( ≥ 75%)
Delvis heling( ≥ 75%)
Partial Clearance( ≥ 75%)
delvis lammelse
partial paralysis
Delvis midlertidig eller permanent nedsættelse eller tab af synet på det ene eller begge øjne er set sjældent.
Partial, temporary, or permanent decrease or loss of vision in one or both eyes has been rarely reported.
Delvis remission4
Partial remission4
Delvis respons
Partial response
Delvis respons %
Partial response
Delvis respons**** i det primære studie (85)
Partial responders**** in parent study (85)
delvis tab af syn, tørre eller smertefulde øjne
partial loss of vision, dry or painful eyes
Delvis, midlertidig eller permanent nedsættelse eller tab af synet på det ene eller begge øjne og alvorlig allergisk reaktion, som medfører hævelse i ansigtet eller svælget.
Partial, temporary or permanent decrease or loss of vision in one or both eyes and serious allergic reaction which causes swelling of the face or throat.
Delvist brugte hætteglas skal kasseres.
Partially used vials must be discarded.
Delvist eller fuldstændigt synstab på et eller begge øjne
Partial or complete loss of vision in one or both eyes
Delvist eller totalt synstab
Partial or total loss of vision
Delvist respons
Partial Response
Delvist respons (PR)
Partial response (PR)
Delvist respons (PR) [n (%)]
Partial response (PR) [n (%)]
Delvist respons blev opnået af 32,1% af patienterne i metastatiske basalcellekarcinom- kohorten og 35,1% af patienter i lokalt fremskredent basalcellekarcinom kohorten.
Partial response was achieved in 32.1% patients in the mBCC cohort and 35.1% in the laBCC cohort.
delvist synstab
partial loss of vision
delvist tab af bevægelsesevne
partial loss of movement
Dematitis på infusionsstedet
Infusion site dermatitis
Demens associeret med Parkinsons sygdom
Dementia associated with Parkinson’s Disease
Demens, associeret med Parkinsons sygdom
Dementia associated with Parkinson's Disease
Demens, associeret med Parkinsons sygdom
Dementia associated with Parkinson’s Disease
Demens, der er associeret med Parkinsons sygdom
Dementia associated with Parkinson's Disease
Demens, der er associeret med Parkinsons sygdom
Dementia associated with Parkinson’s Disease
Demografi og sygdomskarakteristika ved baseline (interimanalyse-populationen) var sammenlignelige mellem Xofigo og placebogrupperne, og vises nedenfor for Xofigo: den gennemsnitlige alder for patienterne var 70 år (interval fra 49 til 90 år).
Demographic and baseline disease characteristics (interim analysis population) were similar between the Xofigo and placebo groups and are shown below for Xofigo: the mean age of patients was 70 years (range 49 to 90 years).
Demografi og sygdomskarakteristika ved baseline var generelt velafbalanceret mellem de 2 behand- lingsgrupper: Patienternes medianalder var 66 år, 74% var mænd, 66% var af kaukasisk oprindelse og 32% asiatiske, 69% af patienterne havde positivt knoglemarvsaspirat og/eller positiv knoglemarvsbiopsi for MCL, 54% af patienterne havde en IPI-score (International Prognostic Index) på ≥ 3, og 76% havde sygdom i stadie IV.
The demographic and baseline disease characteristics were generally well balanced between the two treatment arms: median patient age was 66 years, 74% were male, 66% were Caucasian and 32% Asian, 69% of patients had a positive bone marrow aspirate and/or a positive bone marrow biopsy for MCL, 54% of patients had an International Prognostic Index (IPI) score of ≥ 3, and 76% had Stage IV disease.
Demografi, inklusiv alder, race og ECOG performance status (0 til 2) var afbalanceret mellem behandlingsarmene.
Demographics, including age, race, and ECOG performance status (0 to 2), were balanced between the treatment arms.
Demografien var velbalanceret (median-alder 49-50 år, størstedelen var kaukasiere (71 %)) og alle patienter var kvinder.
Demographics were well balanced (median age was 49-50 years, the majority were caucasian (71%)) and all patients were female.
Demografien var velbalanceret imellem behandlingsarmene (median-alder 49-50 år, størstedelen var kaukasiere (77 %)), og alle patienter var kvinder.
Demographics were well balanced between arms (median age was 49-50 years, the majority were Caucasian [77%]) and all patients were female.
Demografikarakteristika
Demographic Characteristics
Demografiske data og baseline-karakteristika var ligeligt fordelt mellem behandlingsgrupperne.
The demographics data and baseline characteristics were well balanced between the treatment groups.
Demografiske eller baseline- karakteristika
Demographic or baseline characteristic
Demografiske karakteristika
Demographic characteristics
Demografiske karakteristika og baseline-karakteristika for studie 2011-003 var velafbalancerede mellem de to behandlingsarme, herunder tidligere behandling med bortezomib (54 %), tidligere behandling med lenalidomid (38 %), refraktær for lenalidomid (25 %), alder (65 år, interval 30-89 år), køn (51 % mænd), ECOG-status (45 % med ECOG-status 1), genetiske højrisikomutationer bestående af de genetiske deltyper t(4;14), t(14;16) eller deletion 17p i ≥ 60 % af plasmaceller (23 %) eller genetiske mutationer med ukendt risiko, hvilket omfattede patienter, hvis resultater ikke var indsamlet eller analyseret (9 %), samt sygdom i ISS-stadie III ved baseline (24 %).
The demographics and baseline characteristics for study 2011-003 were well-balanced between the two arms, including prior treatment with bortezomib (54%), prior treatment with lenalidomide (38%), lenalidomide refractory (25%), age (65 years, range 30-89 years), gender (51% male), ECOG performance status (45% with performance status 1), high-risk genetic mutations, consisting of the genetic subtypes t(4;14), t(14;16), or deletion 17p in ≥ 60% of plasma cells (23%) unknown-risk genetic mutations, which included subjects with results not collected or not analysed (9%) and baseline ISS stage III disease (24%).
Demografiske karakteristika og sygdomskarakteristika ved basislinje var afbalancerede mellem de to behandlingsarme.
Baseline demographic and disease characteristics were well balanced between the two treatment arms.
Demografiske og baseline karakteristika
Demographic and baseline characteristics
Demografiske og baseline-sygdomskarakteristika var generelt afbalanceret mellem de to behandlingsarme: Den mediane patientalder var 66 år, 74 % var mænd, 66 % var kaukasere og 32 % asiater, 69 % af patienterne havde et positivt knoglemarvsaspirat og/eller en positiv knoglemarvsbiopsi for MCL, 54 % af patienterne havde en IPI-score (International Prognostic Index) på ≥ 3, og 76 % var i sygdomsstadie IV.
The demographic and baseline disease characteristics were generally well balanced between the two treatment arms: median patient age was 66 years, 74% were male, 66% were Caucasian and 32% Asian, 69% of patients had a positive bone marrow aspirate and/or a positive bone marrow biopsy for MCL, 54% of patients had an International Prognostic Index (IPI) score of ≥ 3, and 76% had Stage IV disease.
Demyelinering: Snæver SMQ ”Demyelinering” (da GBS også er inkluderet i denne SMQ, vil der være et overlap i antallet af tilfælde for disse to kategorier)
Demyelination: narrow SMQ “Demyelination” (as GBS is also included in this SMQ, there will be an overlap in the number of cases for these two categories).
demyeliniserende sygdomme (f.eks. opticus neuritis, Guillain-Barré syndrom) 1)
multiple sclerosis, demyelinating disorders (e.g. optic neuritis, Guillain-Barré syndrome) 1)
demyeliniserende sygdomme (f.eks. optisk neuritis)
demyelinating disorders (e.g. optic neuritis)
Demyelinisering: snæver SMF ”Demyelinisering” (da GBS også er inkluderet i denne SMF, vil der være en overlapning i antal hændelser for disse to kategorier).
Demyelination: narrow SMQ “Demyelination” (as GBS is also included in this SMQ, there will be an overlap in the number of cases for these two categories).
Den
The
Den "emulsion", som er resultatet heraf, kan derefter indsprøjtes.
The resulting ‘emulsion’ is then injected.
Den "våde" form for aldersbetinget makulær degeneration (AMD), der er en sygdom, som angriber den gule plet (nethindens centrale del, der også kaldes makula) i den bageste del af øjet.
the ‘wet’ form of age-related macular degeneration (AMD), a disease which affects the central part of the retina (called the macula) at the back of the eye.
Den %-vise ændring fra baseline i OFF tid var –24% i entacapongruppen og 0% i placebogruppen i undersøgelse I. De tilsvarende resultater er –18% og –5% for undersøgelse II.
The % change from baseline in OFF time was -24% in the entacapone group and 0% in the placebo group in study I. The corresponding figures in study II were –18% and –5%.
Den %-vise ændring fra baseline i OFF tid var –24% i entacapongruppen og 0% i placebogruppen i undersøgelse I. De tilsvarende resultater er –18% og –5% for undersøgelse II.
The % change from baseline in OFF time was –24% in the entacapone group and 0% in the placebo group in study I. The corresponding figures in study II were –18% and –5%.
Den 1-årige og 2- årige overlevelsesrate for patienterne i behandling med ALIMTA var henholdsvis 58 % og 32 % sammenlignet med 45 % og 21 % for patienterne i placebo-behandling.
The 1 year and 2 year survival rates for patients on ALIMTA were 58% and 32% respectively, compared to 45% and 21% for patients on placebo.
Den 1-årige og 2- årige overlevelsesrate for patienterne i behandling med pemetrexed var henholdsvis 58 % og 32 % sammenlignet med 45 % og 21 % for patienterne i placebo-behandling.
The 1 year and 2 year survival rates for patients on pemetrexed were 58 % and 32 % respectively, compared to 45 % and 21 % for patients on placebo.
Den 1-årige og 2- årige overlevelsesrate for patienterne i behandling med pemetrexed var henholdsvis 58 % og 32 % sammenlignet med 45 % og 21 % for patienterne i placebobehandling.
The 1 year and 2 year survival rates for patients on pemetrexed were 58% and 32% respectively, compared to 45% and 21% for patients on placebo.
Den 1-års hændelsesfrie rate var 52,6 % (± 5,72 %) for Pom + LD-Dex-armen og 28,4 % (± 7,51 %) for HD- Dex-armen.
The 1-year event free rate was 52.6% (± 5.72%) for the Pom + LD-Dex arm and 28.4% (± 7.51%) for the HD-Dex arm.
Den 144-ugers, dobbeltblinde, aktivt kontrollerede fase af studie GS-99-903 vurderede effekten og sikkerheden af 245 mg tenofovirdisoproxil (som fumarat) versus stavudin ved anvendelse i kombination med lamivudin og efavirenz hos behandlingsnaive hiv 1-inficerede voksne patienter.
The 144-week, double-blind, active controlled phase of study GS-99-903 evaluated the efficacy and safety of tenofovir disoproxil 245 mg (as fumarate) versus stavudine when used in combination with lamivudine and efavirenz in HIV-1 infected adult patients naïve to antiretroviral therapy.
Den 18 G, 5-mikron filterkanyle, som leveres i æsken med 1 ml steril Luer-lock- injektionssprøjte, sættes på.
Attach the 18 G, 5-micron filter needle supplied in the carton to a 1-ml sterile, Luer-lock syringe.
Den 18 G, 5-mikron-filterkanyle, som leveres i æsken med 1 ml steril Luer-lock-injektionssprøjte, sættes på.
Attach the 18 G, 5-micron filter needle supplied in the carton to a 1 ml sterile Luer-lock syringe.
den 31. marts 2025
31 March 2025
Den 4-ugers dobbeltblindede periode blev efterfulgt af en 8-ugers ublindet periode, under hvilken methylnaltrexonbromid skulle anvendes efter behov, men ikke oftere end én gang daglig.
The 4-week, double-blind period was followed by an 8-week, open-label period during which methylnaltrexone bromide was to be used as needed, but no more frequently than once daily.
Den 50 % hæmmende koncentration (IC50) for amprenavir varierede fra 0,012 til 0,08 M i akut inficerede celler og var 0,41 M i kronisk inficerede celler (1 M = 0,50 g/ml).
The 50% inhibitory concentration (IC50) of amprenavir ranged from 0.012 to 0.08 M in acutely infected cells and was 0.41 M in chronically infected cells (1 M = 0.50 g/ml).
Den 9 mg/ml (0,9 %) injektionsopløsning af natriumklorid føjes til hætteglasset ved at trykke sprøjtens stempel ned med en langsom, fast bevægelse.
The sodium chloride 9 mg/ml (0.9%) solution for injection is added to the vial by slow, firm depression of the syringe plunger.
Den absolutte biotilgængelighed (70%) for insulin glulisin var ækvipotent for injektionsstederne, og der var en lav intra-patient variabilitet (11%).
The absolute bioavailability (70%) of insulin glulisine was similar between injection sites and of low intra-subject variability (11%CV).
Den absolutte biotilgængelighed (70%) for insulin glulisin var ækvipotent for injektionsstederne, og der var en lav intra-patient variabilitet (11%CV).
The absolute bioavailability (70%) of insulin glulisine was similar between injection sites and of low intra-subject variability (11%CV).
Den absolutte biotilgængelighed af asenapin, når den sluges, er lav (< 2 % med en oral tabletformulering).
The absolute bioavailability of asenapine when swallowed is low (< 2 % with an oral tablet formulation).
Den absolutte biotilgængelighed af betain, vandfri, er ikke blevet bestemt.
The absolute bioavailability of betaine anhydrous has not been determined.
Den absolutte biotilgængelighed af den filmovertrukne tablet- formulering er ikke fastlagt.
The absolute bioavailability of the film-coated tablet formulation has not been determined.
Den absolutte biotilgængelighed af emtricitabin fra 200 mg hårde kapsler blev estimeret til 93%.
The absolute bioavailability of emtricitabine from 200 mg hard capsules was estimated to be 93%.
Den absolutte biotilgængelighed af emtricitabin fra Emtriva 200 mg hårde kapsler blev vurderet til at være 93%, og den absolutte biotilgængelighed fra Emtriva 10 mg/ml oral opløsning blev vurderet til at være 75%.
The absolute bioavailability of emtricitabine from Emtriva 200 mg hard capsules was estimated to be 93% and the absolute bioavailability from Emtriva 10 mg/ml oral solution was estimated to be 75%.
Den absolutte biotilgængelighed af en dosis på 100 mg er 23 % og estimeres til 33 % for 300 mg.
The absolute bioavailability of a 100 mg dose is 23% and is predicted to be 33% at 300 mg.
Den absolutte biotilgængelighed af methoxypolyethylenglycol- epoetin beta efter subkutan administration var 54 %.
The absolute bioavailability of methoxy polyethylene glycol-epoetin beta after subcutaneous administration was 54%.
Den absolutte biotilgængelighed af oral abacavir og lamivudin hos voksne er henholdsvis omkring 83 % og 80- 85 %.
The absolute bioavailability of oral abacavir and lamivudine in adults is about 83% and 80-85% respectively.
Den absolutte biotilgængelighed af Tagrisso er ikke bestemt.
The absolute bioavailability of TAGRISSO has not been determined.
Den absolutte biotilgængelighed af vemurafenib 240 mg tabletten er ikke kendt.
The absolute bioavailability of the vemurafenib 240 mg tablet is unknown.
Den absolutte biotilgængelighed efter den første og tredje subkutane administration var fra 45,8 til 98,4 %, med den mediane Tmax fra 24,2 til 48,1 timer.
The absolute bioavailability after the first and third subcutaneous administration ranged from 45.8 to 98.4%, with median Tmax ranging between 24.2 to 48.1 hours.
Den absolutte biotilgængelighed efter oral administrering blev bestemt til 33 %.
The absolute bioavailability after oral administration was found to be 33 %.
Den absolutte biotilgængelighed efter subkutan adminstration af 100 mikrogram parathyreoideahormon i abdomen er 55 %.
The absolute bioavailability of 100 micrograms of parathyroid hormone after subcutaneous administration in the abdomen is 55.
Den absolutte biotilgængelighed er 58% (48-70%1).
The absolute bioavailability is 58% (48-70%1).
Den absolutte biotilgængelighed er 86%±18%.
The absolute bioavailability is 86±18%.
Den absolutte biotilgængelighed er 88%.
The absolute bioavailability is 88%.
Den absolutte biotilgængelighed er mellem 64% og 80%.
Absolute bioavailability has been estimated to be between 64 and 80 %.
Den absolutte biotilgængelighed for cetrorelix efter subkutan indgivelse er cirka 85%.
The absolute bioavailability of cetrorelix after subcutaneous administration is about 85%.
Den absolutte biotilgængelighed for Instanyl er omkring 89 %.
The absolute bioavailability of Instanyl is about 89.
Den absolutte biotilgængelighed for liraglutid er cirka 55 % efter subkutan administration.
Absolute bioavailability of liraglutide following subcutaneous administration is approximately 55%.
Den absolutte biotilgængelighed var 74%.
The absolute bioavailability was 74%.
Den absolutte forskel i objektiv bløddelsrespons mellem enzalutamid- og placebogruppen var 53,9 % (95 % KI: 48,5 %; 59,1 %, p < 0,0001).
The absolute difference in objective soft tissue response between enzalutamide and placebo arms was 53.9% (95% CI: 48.5%, 59.1%, p < 0.0001).
Den absolutte orale biotilgængelighed er ikke fastlagt.
The absolute oral bioavailability has not been determined.
Den absolutte orale biotilgængelighed er næsten 100 %.
Oral absolute bioavailability is close to 100 %.
Den absolutte orale biotilgængelighed for duloxetin ligger på 32-80 % (gns. på 50 %).
The absolute oral bioavailability of duloxetine ranged from 32% to 80% (mean of 50%).
Den absolutte orale biotilgængelighed for duloxetin ligger på 32-80% (gns. på 50%).
The absolute oral bioavailability of duloxetine ranged from 32% to 80% (mean of 50%).
Den absolutte orale biotilgængelighed for duloxetin lå på 32-80% (gns. på 50%, N = 8 patienter).
The absolute oral bioavailability of duloxetine ranged from 32% to 80% (mean of 50%).
Den absolutte, orale biotilgæn- gelighed af eltrombopag efter administration til mennesker er ikke fastlagt.
The absolute oral bioavailability of eltrombopag after administration to humans has not been established.
Den accelererede fase er en mellemfase mellem den kroniske fase og indtræden af blastkrisen og anses som det første tegn på behandlingsresistens.
Accelerated phase is an intermediate phase among the chronic phase and the onset of the blast crisis; it is considered as the first manifestation of resistance to therapy.
Den accelererede fase er en mellemfase mellem den kroniske fase og indtræden af blastkrisen og anses som det første tegn på resistens over for behandlingen.
Accelerated phase is an intermediate phase among the chronic phase and the onset of blast crisis; it is considered as the first manifestation of resistance to therapy.
Den adfærdsmæssige udvikling og reproduktionsudviklingen hos afkommet var ikke påvirket, men nogle parametre for fysisk udvikling viste nogen forsinkelse, som sikkert er sekundær til de farmakologi- baserede CNS-virkninger af perampanel.
Behavioural and reproductive development of the offspring was not affected, but some parameters of physical development showed some delay, which is probably secondary to the pharmacology-based CNS effects of perampanel.
Den admini- strerede aktivitet skal i alle tilfælde være så lav som rimeligt muligt for at opnå de nødvendige diagnostiske oplysninger.
The activity administered should in every case be as low as reasonably achievable to obtain the required diagnostic information.
Den administrerede dosis bør baseres på veterinære vurderinger udført ugentligt de første 6 uger, og derefter hver 6. uge.
The dose given should be based on veterinary assessments conducted weekly for the first six weeks and, thereafter, every six weeks.
Den administrerede dosis svarer til 500.000 til 1.000.000 autologe celler/cm2 implantationsmatrix.
The administered dose corresponds to 500,000 to 1,000,000 autologous cells/cm2 of implantation matrix.
Den af glukokortikoider forårsagede stigning i alkalisk fosfatase kan være forbundet med hepatomegali og forhøjede leverenzymer i serum.
The increase of alkaline phosphatase by glucocorticoids could be related to enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes.
Den af investigator vurderede bekræftede responsrate hos patienterne med metastatisk BRAF V600E- mutationspositivt melanom (n = 76) var 59 % (95 % CI: 48,2; 70,3), og den mediane varighed af respons var 5,2 måneder (95 % CI: 3,9; kunne ikke beregnes) baseret på en median opfølgningstid på 6,5 måneder.
The investigator assessed confirmed response rate in patients with BRAF V600E metastatic melanoma (n=76) was 59% (95% CI: 48.2, 70.3) and the median duration of response was 5.2 months (95% CI: 3.9, not calculable) based on a median follow-up time of 6.5 months.
Den afgivne stråling registreres på PET- skanningen, så lægerne kan se, om der er nævneværdige mængder plak til stede.
The radiation it emits can be detected on the PET scan, enabling doctors to see whether or not significant amount of plaques are present.
Den aftagelige etiket på den fyldte injektionssprøjte til sporing af lægemidlet skal klæbes ind i patientens journal for at sikre akkurat registrering af anvendt gadolinium-kontrastmiddel.
The peel-off tracking label on the pre-filled syringes should be stuck onto the patient record to enable accurate recording of the gadolinium contrast agent used.
Den aftagelige etiket på den fyldte injektionssprøjte til sporing af lægemidlet skal klæbes ind i patientens journal for at sikre akkurat registrering af anvendt gadolinium-kontrastmiddel.
The peel-off tracking label on the pre-filled syringes should be stuck onto the patients record to enable accurate recording of the gadolinium contrast agent used.